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Abstract
BACKGROUND—For egg allergy, dietary avoidance is the only currently approved treatment.
We evaluated oral immunotherapy using egg-white powder for the treatment of children with egg
allergy.
METHODS—In this double-blind, randomized, placebo-controlled study, 55 children, 5 to 11
years of age, with egg allergy received oral immunotherapy (40 children) or placebo (15). Initial
dose-escalation, build-up, and maintenance phases were followed by an oral food challenge with
egg-white powder at 10 months and at 22 months. Children who successfully passed the challenge
at 22 months discontinued oral immunotherapy and avoided all egg consumption for 4 to 6 weeks.
At 24 months, these children underwent an oral food challenge with egg-white powder and a
cooked egg to test for sustained unresponsiveness. Children who passed this challenge at 24
months were placed on a diet with ad libitum egg consumption and were evaluated for
continuation of sustained unresponsiveness at 30 months and 36 months.
RESULTS—After 10 months of therapy, none of the children who received placebo and 55% of
those who received oral immunotherapy passed the oral food challenge and were considered to be
desensitized; after 22 months, 75% of children in the oral-immunotherapy group were
desensitized. In the oral-immunotherapy group, 28% (11 of 40 children) passed the oral food
challenge at 24 months and were considered to have sustained unresponsiveness. At 30 months
and 36 months, all children who had passed the oral food challenge at 24 months were consuming
egg. Of the immune markers measured, small wheal diameters on skin-prick testing and increases
in egg-specific IgG4 antibody levels were associated with passing the oral food challenge at 24
months.
CONCLUSIONS—These results show that oral immunotherapy can desensitize a high
proportion of children with egg allergy and induce sustained unresponsiveness in a clinically
Copyright © 2012 Massachusetts Medical Society.
Address reprint requests to Dr. Burks at the University of North Carolina, Department of Pediatrics, 260 MacNider, Bldg., Campus
Box 7220, Chapel Hill, NC, 27599-7220, or at wburks@email.unc.edu.
Drs. Burks and Jones contributed equally to this article.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
NIH Public Access
Author Manuscript
N Engl J Med. Author manuscript; available in PMC 2013 January 19.
Published in final edited form as:













significant subset. (Funded by the National Institutes of Health; ClinicalTrials.gov number,
NCT00461097.)
In the United States, 4% of children have a food allergy,1 which affects health and quality of
life.2 Egg allergy has a cumulative prevalence of approximately 2.6% by 2.5 years of age,3
with allergic reactions varying in severity from mild urticaria to systemic anaphylaxis.
Severe allergic reactions can occur with a single bite of cooked egg (approximately 70 mg of
egg protein). Children with egg allergy are placed on egg-free diets, but total avoidance of
egg is difficult. Avoidance places a constant responsibility on patients and caregivers, leaves
patients vulnerable to unintentional ingestion and anaphylaxis, and influences quality of
life.4,5
Given these challenges, new treatment strategies are being explored. The goal of allergen
immunotherapy is to produce a more sustained clinical effect than desensitization, including
immune tolerance (i.e., long-term loss of allergic reactivity after discontinuation of therapy).
Desensitization, a state in which the threshold dose of food that triggers an allergic reaction
is raised during therapy, is more easily achieved. Traditional subcutaneous immunotherapy,
which is effective against certain aeroallergens,6,7 is unsafe for the treatment of food
allergy.8,9 Oral immunotherapy appears to be safer than subcutaneous immunotherapy for
food allergens and induces desensitization. Oral immunotherapy has been successful in
desensitizing patients to several food allergens in small clinical trials, most of which were
not controlled. 10–20 In the current study, we did not study the induction of immune
tolerance, but we assessed what we call “sustained unresponsiveness,” defined as the ability,
after 22 months of oral immunotherapy and subsequent avoidance of egg consumption for 4
to 6 weeks, to consume 10 g of egg-white powder and a whole cooked egg without clinically
significant symptoms. In addition, children who passed the oral food challenge at 24 months
were placed on an ad libitum diet and followed for 12 more months.
We conducted a multicenter, double-blind, randomized, placebo-controlled study of the
effectiveness and safety of oral immunotherapy, including its capacity to induce sustained
unresponsiveness, in children with egg allergy.
METHODS
STUDY DESIGN AND PARTICIPANT SELECTION
The primary end point of the study was the induction of sustained unresponsiveness after 22
months of oral immunotherapy with egg. Secondary end points included desensitization,
which was defined as the ability to pass an oral food challenge with 5 g of egg-white powder
at 10 months and with 10 g at 22 months, while still receiving daily oral immunotherapy,
and the safety of oral immunotherapy. The study protocol is available with the full text of
this article at NEJM.org.
Eligible participants were 5 to 18 years of age and had a convincing clinical history of egg
allergy (shown by the development of allergic symptoms within minutes to 2 hours after
ingesting egg) and a serum egg-specific IgE antibody level of more than 5 kU per liter for
children 6 years of age or older, or 12 kU per liter or more for those 5 years old. These
levels were chosen to exclude children who were likely to outgrow the allergy during the
course of the study.21,22 Children with a history of severe anaphylaxis (i.e., previous
hypotension) after egg consumption were excluded.
STUDY OVERSIGHT
The study protocol and consent forms were approved by the institutional review board at
each clinical site. The study was conducted under an investigational new drug application to
Burks et al. Page 2













the Food and Drug Administration and was monitored by an independent data and safety
monitoring board from the National Institute of Allergy and Infectious Diseases. Written
informed consent was obtained from parents or guardians, with assent from children older
than 7 years of age.
The authors attest to the veracity and completeness of the data and analyses as well as to the
fidelity of the study to the protocol. Raw egg-white powder was purchased from a
commercial manufacturer (Deb-El Food Products). Immune-testing reagents were provided
at a discounted rate by Greer Laboratories and Phadia.
RANDOMIZATION AND DOSING
The participants were randomly assigned by means of a centralized computer algorithm to
receive either double-blind oral immunotherapy with egg or placebo (in a ratio of 8:3) at five
clinical sites (with a total of 40 children receiving oral immunotherapy, and 15 placebo).
The study was blinded through the first oral food challenge at 10 months (Fig. 1).
Thereafter, placebo was stopped, and the children in the placebo group were followed
through 24 months, whereas treatment was continued in the oral-immunotherapy group on
an open-label basis. Egg-white powder and matching placebo (cornstarch) were weighed
and put into vials at a central pharmacy and then distributed to the pharmacies at the study
sites.
ORAL-IMMUNOTHERAPY PROTOCOL
The protocol for oral immunotherapy consisted of three phases: an initial-day dose
escalation, a build-up phase, and a maintenance phase during which participants ingested up
to 2 g of egg-white powder per day, which is the approximate equivalent of one third of an
egg (see the Supplementary Appendix, available at NEJM.org). The children and their
families were instructed that the children should avoid egg consumption other than the oral
immunotherapy. The severity of allergic reactions was reported with the use of a customized
grading system, with scores ranging from 1 (transient or mild discomfort) to 5 (death) (Table
S1 in the Supplementary Appendix).
ORAL FOOD CHALLENGE AND FOLLOW-UP
At 10 months, all participants underwent an oral food challenge consisting of 5 g
(cumulative dose) of egg-white powder. Participants who passed (i.e., consumed who
received the placebo were given a subsequent oral food challenge only if the egg-specific
the entire amount without having clinically significant allergic symptoms) were considered
to be desensitized. Children IgE antibody level was less than 2 kU per liter — a cutoff
defined on the basis of risks associated with oral food challenges in children who did not
pass an oral food challenge during the previous year and the association of not passing an
oral food challenge with elevated levels of egg-specific IgE antibody. 21,23 Children who
received oral immunotherapy underwent a second oral food challenge, with a dose of 10 g of
egg-white powder, at 22 months. The children who passed the oral food challenge at 22
months discontinued oral immunotherapy and avoided any egg consumption for 4 to 6
weeks. At 24 months, these children were given an oral food challenge of 10 g of egg-white
powder, followed 1 hour later by feeding of a whole cooked egg.
The oral food challenge was scored as pass (consumption of the total dose of egg with no
clinically significant allergic symptoms) or fail (inability to consume the total dose because
of persistent allergic symptoms such as hives, wheezing, vomiting, or laryngeal edema). The
scorer was unaware of the study assignments through 10 months. Participants who passed
the oral food challenge at 24 months and consumed the whole cooked egg were instructed to
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add egg to their diet ad libitum and to report any adverse events. Egg consumption and
adverse events were ascertained by telephone or at clinic visits at 30 months and 36 months.
IMMUNE MARKERS
Skin-prick testing with egg extract (Greer Laboratories) and saline and histamine controls
was performed at enrollment and at 10 months and 22 months. Basophil activation was
measured according to CD63 up-regulation on flow cytometry. 24 Serum egg-specific IgE
and IgG4 antibody levels were measured with the use of the Immuno-CAP 100 (Thermo
Fisher Scientific).
STATISTICAL ANALYSIS
We calculated that a sample of 55 participants (40 receiving oral immunotherapy, and 15
placebo) would provide 84% power, at a two-sided alpha level of 0.05, to detect a
significant between-group difference in the rate of sustained unresponsiveness, assuming an
estimated 10% rate in the placebo group and an estimated 50% rate in the oral-
immunotherapy group. All clinical outcomes were assessed by intention-to-treat analysis.
Rates of sustained unresponsiveness were tested with Barnard’s test, and an exact
confidence interval for the between-group difference in the response rate was calculated.
The Wilcoxon rank-sum test was used to evaluate between-group differences in changes
from baseline in skin-prick test results (wheal size) and immunoglobulin levels. Basophil
activation and immunoglobulin levels were evaluated in repeated-measurement models, with
the baseline value as a covariate and unstructured within-person covariance. Logistic
regression was used to evaluate the association of selected immune variables with clinical
outcomes All analyses were performed with the use of SAS software, version 9.2 (SAS
Institute), and StatXact software, version 6 (Cytel Software).
RESULTS
STUDY PARTICIPANTS
A total of 55 participants (11 per institution), with a median age of 7 years, were enrolled;
15 received placebo, and 40 oral immunotherapy with egg (Fig. 1 and Table 1). Of these
participants, 91% reported at least one additional food allergy.
ASSESSMENT OF CLINICAL RESPONSES
None of the 15 children who received placebo and 22 of the 40 (55%) who received oral
immunotherapy passed the oral food challenge of 5 g of egg-white powder at 10 months
(95% confidence interval for the difference in the response rate, 30 to 71%; P<0.001) (Table
2). Six additional children in the oral-immunotherapy group consumed the cumulative 5-g
dose but had clinically significant allergic symptoms at the last dose, and the challenge was
deemed a failure in these children. Of the 22 children who passed, 14 had no symptoms, 7
had mild symptoms that resolved without treatment, and 1 had a moderate symptom (throat
discomfort) at the fourth dose that resolved without treatment. The median cumulative dose
successfully consumed during the oral food challenge at 10 months was 5.00 g (range, 0.25
to 5.00) in the oral-immunotherapy group versus 0.05 g (range, 0.00 to 2.75) in the placebo
group (P<0.001).
One child who received placebo had an egg-specific IgE antibody level of less than 2 kU per
liter and underwent the oral food challenge of 10 g of egg-white powder at 22 months; the
child did not pass this challenge. At 22 months, 30 of 40 children (75%) in the oral-
immunotherapy group passed the oral food challenge of 10 g of egg-white powder (Table 2).
The number of children in the oral-immunotherapy group who passed the oral food
challenge increased after 10 months, even though the challenge dose was twice as high at 22
Burks et al. Page 4













months. The median cumulative dose that was successfully consumed by children in the
oral-immunotherapy group during the oral food challenge at 22 months was 10.0 g (range,
1.5 to 10.0).
Of the 30 children who passed the oral food challenge at 22 months, 29 underwent the oral
food challenge at 24 months, and 11 passed. Thus, according to the intention-to-treat
analysis, 11 of the 40 children (28%) in the oral-immunotherapy group passed the oral food
challenge at 24 months (P = 0.03, as compared with placebo) (Table 2). Among the 18
children who underwent this challenge and did not pass, 5 consumed a dose of 7.5 g, 3 a
dose of 3.5 g, 5 a dose of 1.5 g, 4 a dose of 0.5 g, and 1 a dose of 0.1 g. Since no children
who received placebo passed the oral food challenge at 22 months, none were eligible to
undergo the challenge at 24 months; none of the children in the placebo group met the
primary end point.
Of the 22 children who were desensitized at 10 months, 9 (41%) passed the oral food
challenge at 24 months, as compared with 2 of 18 children (11%) who were not desensitized
(P = 0.07). In the oral-immunotherapy group, 9 of the 18 children (50%) who reached the
maintenance dose of 2 g before 10 months passed the challenge at 24 months, as compared
with 2 of the 22 (9%) who did not reach the 2-g dose before 10 months (P = 0.006).
In the group of children who consumed egg ad libitum, no adverse events were reported at
30 months (11 children) or at 36 months (10 children). One participant was lost to follow-up
after 30 months.
IMMUNOLOGIC CORRELATES
Baseline age, sex, and maximum dose on the first day were not predictive of sustained
unresponsiveness. Several a priori, protocol-defined immune variables were evaluated to
identify correlates of successful clinical outcomes over time (Table 3).
Median egg-specific IgG4 antibody levels at 10 months were higher in children who were
desensitized at 10 months (P = 0.007), those who were desensitized at 22 months (P =
0.005), and those who had sustained unresponsiveness at 24 months (P = 0.02), as compared
with children who did not pass the oral food challenge at these time points (Table 3, and Fig.
S1 in the Supplementary Appendix). Similar correlations were found for changes from
baseline in egg-specific IgG4 antibody levels (Fig. S2 in the Supplementary Appendix).
Logistic-regression analysis confirmed these correlations, indicating that egg-specific IgG4
antibody levels at 10 months correlated with desensitization at 10 months and also predicted
desensitization at 22 months and sustained unresponsiveness at 24 months.
At 10 months, egg-specific IgE antibody levels and basophil activation were lower in
children who were successfully desensitized at 22 months than in those who were not (P =
0.02 and P = 0.04, respectively). However, these immune variables did not correlate with
sustained unresponsiveness at 24 months.
The wheal size on skin-prick testing at 22 months was inversely associated with the
likelihood of desensitization at 22 months (P = 0.009) and with sustained unresponsiveness
at 24 months (P = 0.005) (Table 3, and Fig. S3 in the Supplementary Appendix). A decrease
in wheal size from baseline to 22 months was also correlated with sustained
unresponsiveness at 24 months (P = 0.01) (Fig. S4 in the Supplementary Appendix).
Logistic-regression analysis confirmed that a reduced wheal size at 22 months, as compared
with baseline, correlated with sustained unresponsiveness at 24 months.
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As compared with children who received placebo, those who received oral immunotherapy
had a decreased wheal size on skin-prick testing, reduced egg-induced basophil activation,
and increased egg-specific IgG4 antibody levels over time, whereas no change in egg-
specific IgE antibody levels was noted (Fig. S5 through S8 in the Supplementary Appendix).
ADVERSE EVENTS
All 55 children completed the initial-day dose escalation. Seven children (13%) withdrew
before the maintenance phase (2 in the placebo group and 5 in the oral-immunotherapy
group). Of the 2 children in the placebo group who withdrew, 1 discontinued the study after
completion of the initial dose escalation because of allergy-like symptoms and 1 because of
transportation issues. Of the 5 children in the oral-immunotherapy group who withdrew
within 5.5 months after starting therapy, 4 had allergic reactions, and 1 had an anxiety
reaction. One additional child in the oral-immunotherapy group withdrew after the oral food
challenge at 10 months but before the challenge at 22 months, owing to an allergic reaction
associated with dosing (see the Supplementary Appendix).
Adverse events occurred most frequently in association with oral-immunotherapy dosing.
The rates of adverse events were highest during the first 10 months of oral immunotherapy
(Table 4). No severe adverse events occurred. Adverse events, most of which were oral or
pharyngeal, were associated with 25.0% of 11,860 doses of oral immunotherapy with egg
and 3.9% of 4018 doses of placebo. In the oral-immunotherapy group, 78% of children had
oral or pharyngeal adverse events, as compared with 20% of those in the placebo group
(P<0.001). After 10 months, the rate of symptoms in the oral-immunotherapy group
decreased to 8.3% of 15,815 doses (data not shown). In addition to dosing-related
symptoms, 437 other adverse events were reported; 96.0% were considered to be unrelated
to dosing on the basis of the timing and the type of symptoms. All serious adverse events
(three respiratory infections and one allergic reaction to peanuts) were considered to be
unrelated to dosing.
DISCUSSION
Oral immunotherapy has previously been evaluated for its ability to desensitize persons to
foods such as milk, peanuts, and eggs.14–20,26 The current study, unlike previous studies,
enrolled a substantial number of children at multiple sites and showed sustained
unresponsiveness in a double-blind, randomized, controlled study design with long-term
follow-up during ad libitum consumption of the allergen. Two previous studies18,27
evaluating oral immunotherapy for milk and peanut allergies had double-blind, placebo-
controlled designs, but they were smaller than the current study and neither involved more
than two sites. A third study20 showed desensitization and sustained unresponsiveness after
prolonged oral immunotherapy with milk but did not evaluate the ability of the participants
to consume milk ad libitum. Desensitization alone is a therapeutically beneficial state
because it confers protection against allergic reaction to accidental exposure. However,
some participants in oral-immunotherapy studies who had only short-term desensitization
subsequently had allergic symptoms after exposure to the suspect food during viral
infections or after exercise.28 Sustained unresponsiveness, which occurred in 28% of the
children in the current study, appears to be therapeutically more desirable than
desensitization, in that the children had a higher threshold to the food allergen than would be
expected according to the natural history, successfully incorporated egg into their diet, and
were without symptoms at 36 months.
Suppression of mast-cell function, basophil activation, and modulation of lymphocyte
responses are critical for the development of immune tolerance in response to allergen
immunotherapy (e.g., subcutaneous immunotherapy).6,29,30 In the current study, the
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suppression of mast cells, as evidenced by decreased wheal size on skin-prick testing, and
basophil activation were noted in children receiving oral immunotherapy, as compared with
those receiving placebo, through 22 months and correlated with desirable clinical outcomes.
Egg-specific IgG4 antibody levels at 10 months were increased by a factor of more than 100
above baseline values and correlated with sustained unresponsiveness. However, we
identified no threshold elevations of egg-specific IgG4 antibody above the baseline value
that were predictive of sustained unresponsiveness or that could be used as a substitute for
the observed results of an oral food challenge to predict clinical outcomes. Increases in
specific IgG4 antibody levels, with or without decreases in IgE antibody levels, have been
associated with successful immunotherapy31–33 and loss of clinical sensitivity to milk and
egg.18,20,34,35 After immunotherapy, the blocking activity present in serum is associated
with allergen-specific IgG4 antibody, and it may be responsible for long-term immune
tolerance after aeroallergen immunotherapy.36,37
Although the results of the current study are consistent with the induction of sustained
unresponsiveness, the data cannot formally exclude other possibilities. First, the children
who passed the oral food challenge at 24 months might lose the sustained unresponsiveness
if ad libitum egg consumption were discontinued. A more prolonged phase of egg avoidance
after oral immunotherapy might have excluded this possibility, but it was considered
impractical, owing to the difficulty in achieving compliance with longer-term avoidance of
egg. Second, participants in the study might have spontaneously outgrown the egg allergy.
This explanation is unlikely, given the inclusion criteria that predicted a low likelihood of
outgrowing the egg allergy.21,22 Indeed, none of the children who received placebo passed
the oral food challenge at 10 months, one did not pass the challenge at 22 months, and the
others had persistently high levels of egg-specific IgE antibody at 22 months. Third, the
children who passed the oral food challenge at 24 months might not have avoided
consuming egg during the period of 4 to 6 weeks when they were not receiving oral
immunotherapy, but we believe this to be unlikely.
In conclusion, we found that oral immunotherapy provides protection in a majority of
children with egg allergy by raising the reaction threshold and represents a highly promising
therapeutic intervention for food allergy. The approach is relatively safe in that reactions to
dosing were mild (grade 1), with less than 1% of reactions scored as moderate (grade 2).
However, some allergic reactions were of sufficient clinical significance that approximately
15% of the children who received oral immunotherapy did not complete the therapy, in most
cases because of allergic reactions. The mechanisms underlying the success of oral
immunotherapy and their relationship to natural immune tolerance are unknown. For oral
immunotherapy to be recommended as a standard of care, it will be important to better
define the risks of oral immunotherapy versus allergen avoidance, determine the dosing
regimens with the most favorable outcomes, identify patients who are most likely to benefit
from oral immunotherapy, and develop postdesensitization strategies38 that promote long-
term immune tolerance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Study Enrollment, Randomization, and Outcomes
Eligibility criteria included both a convincing clinical history of egg allergy and elevated
levels of egg-specific IgE antibody. No oral food challenge (OFC) was performed at
baseline. The 55 children who met the screening requirements were randomly assigned to
receive placebo or oral immunotherapy (OIT) with egg. After the challenge at 10 months,
the study was unblinded, and all children who had received placebo were followed
longitudinally without further dosing. Children in the placebo group were not eligible for the
challenge at 22 months unless the level of egg-specific IgE antibody was less than 2 kU per
liter. All children in the OIT group continued to receive OIT after the challenge at 10
months, until the challenge at 22 months. Of the 30 children who passed the challenge at 22
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months, 29 stopped receiving OIT for 4 to 6 weeks and then underwent a challenge to assess
sustained unresponsiveness at 24 months. All 11 children who passed the challenge at 24
months were placed on an ad libitum egg diet, with subsequent evaluation at 30 months (11
children) and 36 months (10 children).
Burks et al. Page 11

























Burks et al. Page 12
Table 1








      Median 7.0 7.0
      Range 5.0–10.0 5.0–11.0
Atopic dermatitis score†
      Median 3.0 3.5
      Range 0.0–8.0 0.0–7.0
Total IgE antibody — kU/liter
      Median 1060.9 1095.5
      Range 137.2–3440.9 38.3–10,097.0
Egg-specific IgE antibody — kU/liter
      Median 25.7 10.3
      Range 4.1–89.0 3.7–231.1
Egg-specific IgG4 antibody — mg/liter
      Median 0.3 0.2
      Range 0.0–9.7 0.0–10.8
Wheal diameter on skin-prick testing with egg — mm
      Median 13.0 10.5
      Range 7.5–20.0 2.5–26.0
Age at first allergic reaction to egg — yr
      Median 1.0 1.0
      Range 0.0–5.0 0.0–8.0
Maximum initial-day escalation dose — mg
      Median 50.0‡ 18.5
      Range 50.0–50.0 6.0–50.0
Initial build-up dose — mg




















      Median 50.0‡ 9.0
      Range 12.0–50.0§ 3.0–50.0
Children who consumed a 2-g maintenance dose — no. (%)
      Before oral food challenge at 10 mo 12 (80)‡ 18 (45)
      Before oral food challenge at 22 mo NA 33 (82)
*
There were no significant differences between the placebo group and the oral-immunotherapy group. NA denotes not applicable.
†
Scores for atopic dermatitis range from 0 to 9, with 0 indicating no disease and 9 the most severe disease state.25
‡
The doses for placebo are in milligrams of placebo powder.
§
Data were missing for one child in the placebo group who did not advance to the build-up phase because of an allergic reaction on day 0.
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Table 2
Success Rates on Oral Food Challenge.








(N = 40) P Value
number number (percent)
Desensitization, 5 g at 10 mo 13 35 0 22 (55) <0.001
Desensitization, 10 g at 22 mo   1† 34 0 30 (75) <0.001
Sustained unresponsiveness at 24 mo‡   0 29§ 0 11 (28)    0.03
*
Oral food challenges were not performed in children who withdrew from the study owing to dose-limiting symptoms. Thus, the actual number of
oral food challenges performed is provided.
†
At 22 months, children who received placebo did not undergo another oral food challenge, given a history of not passing an oral food challenge
within the past year, unless the level of antibody declined to less than 2 kU per liter; this decline occurred in only 1 child.
‡
The oral food challenge for sustained unresponsiveness comprised 10 g of egg-white powder and a whole cooked egg. The 95% confidence
interval for the between-group difference in the response rate was 4.3% to 43.9%.
§
Although 30 children initially passed the oral food challenge at 22 months, 1 also underwent a challenge with a whole egg (protocol deviation)
and did not pass, so only 29 underwent the oral food challenge for sustained unresponsiveness.
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